Form 4: Revolution Medicines Director Thilo Schroeder Acquires Shares Through Investment Funds

Director Thilo Schroeder indirectly acquired shares of Revolution Medicines through investment funds he manages, while disclaiming beneficial ownership except for pecuniary interest.

Summary

• Thilo Schroeder, a director at Revolution Medicines, has reported the acquisition of shares through several investment funds.
• The transactions occurred on December 5, 2024, with shares purchased at $46 each.
• 543,478 shares were acquired through Nextech Crossover I SCSP.
• 760,869 shares were acquired through Nextech VIII SCSP.
• Schroeder is a managing member of Nextech Invest AG, the investment advisor for these funds.
• He is deemed to be the beneficial owner of these shares due to his role, but disclaims beneficial ownership except for any pecuniary interest.
• Additionally, Schroeder is associated with Nextech V Oncology S.C.S., SICAV-SIF and Nextech VI Oncology SCSp, which hold 3,590,313 and 1,153,293 shares respectively.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not indicate any positive or negative sentiment. It is a neutral transaction.

Industry Context

This is a standard SEC Form 4 filing, which is common for company directors and officers who transact in their company's stock. It provides transparency into insider trading activity.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The reporting of indirect ownership through investment funds is also a common occurrence.
• The disclaimer of beneficial ownership except for pecuniary interest is a standard legal practice to avoid undue liability.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider trading activity.
• The indirect acquisition of shares by a director may be viewed positively by some investors as a sign of confidence in the company.

Key Dates

Keywords

Revolution Medicines, RVMD, Thilo Schroeder, insider trading, share acquisition, Nextech Invest AG, beneficial ownership, investment funds